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Objectives To investigate the prevalence, persistence and genome heterogeneity of transfusion-transmitted
(TTV) in HIV-1-infected patients, a group at high risk both of contracting blood-borne viruses and having
viral persistence relating to immunodepression.
Methods Plasma samples from 238 HIV-1 seropositive subjects and 226 healthy blood donors were examined
for TTV-DNA both by polymerase chain reaction (PCR) using primers from the conserved regions in the
N22 clone and PCR using primers deduced from the untranslated region (UTR). Direct DNA sequencing
and phylogenetic analysis were used to characterize 27 TTV isolates from HIV-1 patients or healthy controls.
Results Using PCR with the UTR primers, TTV DNA was detected in a very high percentage ( 80%) of
samples both from HIV-1 seropositive subjects and from blood donors. Using PCR with N22 primers, shown
to detect viral strains associated with hepatitis of unknown etiology, TTV DNA was found in 103 of 238
(43.3%) HIV-1-infected patients and in 22 of 226 (9.7%) blood donors. There was no difference in the
prevalence of the TTV DNA in HIV seropositive subjects with regard to clinical features related to
immunosuppression, markers of HCV infection or intravenous drug use; presence of TTV DNA was associated
significantly only with male gender (P = 0.003). Persistent or intermittent viremia was detected in plasma
samples taken up over a period of 19 months in all (15 of 15) HIV-infected patients tested.
Conclusions The persistence and high frequency of infection detected by PCR with N22 primers in HIV-1
seropositive patients suggest that further clinical investigation of immunocompromised hosts will provide
information to clarify the pathogenic role of TTV.
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INTRODUCTION
Transfusion-transmitted virus (TTV) DNA has recently been
identified in patients with post-transfusion hepatitis of
unknown etiology in Japan [1]. TTV sequences were detected
by polymerase chain reaction (PCR) with heminested primers
deduced from the N22 region in serum samples from a sig-
nificantly higher percentage of patients with fulminant or cryp-
togenic liver disease than in symptom-free blood donors in
Japan and North America, suggesting an association between
TTV and hepatitis [2,3]. Furthermore, among patients with
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chronic liver disease, TTV DNA occurred in those with liver
cirrhosis and hepatocellular carcinoma more frequently than in
those with chronic hepatitis [4].
Despite these data, clinical and epidemiological studies in the
UK and Germany have not been able to ascribe any substantial
role to TTV in inducing hepatitis or severe liver disease, and
the high prevalence of TTV DNA in different geographically
separated human populations and in different population
groups, including blood donors, raises doubts about whether
this virus is pathogenic to humans [5–9].
Phylogenetic analysis of TTV isolates collected from different
countries provided evidence for TTV genome heterogeneity
and the existence of several viral types and subtypes [2,5,7,10–
12]. At present, 16 genotypes have been identified that are
separated by an evolutionary distance of  0.30, hence the
regions of the genome used to design primers can influence the
detection of TTV-DNA significantly [13].
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Recently Takahashi has reported a positive rate that was
much higher with primers deduced from the untranslated
region (UTR) than primers deduced from the coding N22
region [14]. Later on, Okamoto proved that this difference was
not due to different sensitivities between the two sets of primers
but could be ascribed to distinct specificities between the UTR
and the N22 primers [13]. PCR with N22 primers could detect
some genotypes of TTV, but not others. In contrast a preva-
lence of  90% of continuing TTV infection in the general
population could be detected by PCR with various sets of
UTR primers. It should also be pointed out that an association
of some TTV genotypes detectable by PCR with N22 primers
with hepatitis of unknown etiology suggests that only certain
genotypes are important clinically [2–4,15].
In this context, further studies including establishing the
prevalence of TTV DNA detectable by PCR with N22 and
UTR primers in different population groups, persistence of
infection in individual subjects and genome heterogeneity in
the strains associated with hepatitis of unknown etiology are
needed to elucidate the true epidemiological profile of the virus
and its short- and long-term consequences.
In the current study we carried out a large-scale comparison
on the prevalence of TTV strains detected with N22 and UTR
primers in HIV-1 seropositive patients, a population group up
to now not examined and one at high risk both for parenteral
transmission of infectious agents and the possibility of viral
persistence and severe disease related to immunodepression.
We also analyzed the prevalence of the TTV DNA in healthy
blood donors and the genome heterogeneity of the strains
associated with hepatitis of unknown etiology circulating in
Italy.
MATERIALS AND METHODS
Patients
The prevalence of TTV infection was determined in two
groups:
Blood donors
Samples were collected from 226 blood donors (130 males, 96
females) who donated blood between January and March 1999,
in the Blood Transfusion Centre of the Policlinico S. Matteo,
Pavia (Northern Italy) and of the Ospedale S. Carlo, Potenza
(Southern Italy). All were regular donors, with normal liver-
function tests and were negative for antibodies to hepatitis C
virus (HCV), HIV-1, HIV-2, and hepatitis B virus (HBV)
surface antigen.
HIV-1-infected patients
Samples were collected from 238 HIV-1-infected patients
attending the Department of Infectious and Tropical Diseases
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of the University of Pavia. According to the CDC (Centers for
Disease Control) classification system, 151 patients were at stage
A (49, A1; 91, A2; 11, A3), 29 were at stage B (1, B1; 16, B2;
12, B3) and 39 at stage C (2, C2; 37, C3). There were 168
males and 70 females with a mean age of 37 years; 140 (58.8%)
were intravenous drug users (IVDUs) and 195 (81.9%) were
positive for HCV RNA. In 97 of 98 patients who were not
IVDUs, the risk factor for HIV infection was sexual transmission
and in the remaining patient it was blood tranfusion. Serum
alanine aminotransferase (ALT), aspartate aminotransferase
(AST), g-glutamil transpeptidase (g-GPT) and total bilirubin
levels were also recorded.
Sample preparation
Plasma samples were separated from whole blood by cen-
trifugation at 1800 g for 10 min within 3 h of collection and
immediately frozen in 200-mL aliquots at 80 °C until thawed
for DNA extraction.
DNA was extracted from 150 mL of EDTA-anticoagulated
plasma using Helix Speed Virus kit (Dia Tech, Jesi, AN, Italy)
and resuspended in 50 mL elution buffer. TTV DNA was ampli-
fied both by semi-nested PCR with TTV-specific primers
derived from the N22 coding region of the published sequences
(N22 PCR) [2] and by one-stage PCR with primers deduced
from the untranslated region (UTR PCR) [13]. In brief, for
the first round of N22 PCR, 10 pmol primer NG059 (sense:
5?-ACA GAC AGA GGA GAA GGC AAC ATG-3?) and
10 pmol primer NG063 (antisense: 5?-CTG GCA TTT TAC
CAT TTC CAA AGT T-3?) were added to a 50-mL PCR
mixture containing  1 PCR buffer (50 mM NaCl, 10 mM
Tris-HCl (pH 8.3)) 0.2 mM deoxynucleoside triphosphates,
2 mM magnesium chloride, and 1.5 U Taq polymerase (PE Bio-
systems, Foster City, CA, USA). Amplification was for 35 cycles
at 94 °C for 30 s, 58 °C for 30 s, and 72 °C for 45 s (with a
final extension step at 72 °C for 7 min) in a Perkin Elmer (PE
Biosystems) 2400 thermocycler. One microliter of amplified
DNA was subjected to a second round of PCR with another
sense primer NG061 (5?-GGC AAC ATG TTA TGG ATA
GAC TGG-3?) and the same antisense primer NG063, in a
final reaction volume of 50 mL, for 30 cycles at 94 °C for 30 s,
58 °C for 30 s, 72 °C for 30 s, with a final extension step at
72 °C for 7 min. The size of the amplified fragment obtained in
the second-round PCR was 271 bp. For UTR PCR, 10 pmol
primer NG133 (sense 5?GTA AGT GCA CTT CCG AAT
GGC TGA G-3?) and 10 pmol NG 147 primer (antisense 5-
GCC AGT CCC GAG CCC GAA TTG CC-3?) were used
in 50 mL of the same PCR mixture described for N22 PCR.
The amplification was for 55 cycles at 94 °C for 30 s, 60 °C for
40 s and 72 °C for 45 s (with a final extension at 72 °C for
7 min) The size of the amplified fragment was 143 bp.
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Positive and negative results were confirmed with repeated
assays.
The PCR fragments obtained from N22 PCR were purified
with PCR product presequencing kit (Amersham Life Science,
Cleveland, OH, USA) and subjected to direct sequencing from
both directions using the Dye Terminator Cycle Sequencing
kit in a ABI 310 automated sequencer (PE Biosystem). Newly
obtained sequences were compared with TTV sequences
reported earlier [2] by means of phylogenetic analysis, which
was performed by neighbour joining of Jukes-Cantor corrected
P distances using the MEGA package [17]. The evaluation
of the significance of the grouping was assessed by bootstrap
resampling (1000 times).
Statistical analysis
A preliminary descriptive analysis was performed; quantitative
characteristics between positive and negative patients for TTV
DNA were compared by means of the Mann–Whitney U-test
and qualitative variables by means of the chi-square test. A P-
value  0.05 was considered statistically significant and all the
tests were two-tailed. A logistic regression analysis was per-
formed to evaluate the relation between some demographic
and clinical variables and the presence of the TTV DNA in
plasma samples. Odds ratios (OR) and 95% confidence intervals
(CI) were calculated and reported.
Table 1 Comparison of HIV-1-seropositive patients with and without TTV DNA
Detection of TTV DNA
Positive Negative
Features (n = 103) (%) (n = 135) (%) Differences
Clinical stage NSc
A 59 (39.07%) 92 (60.93%)
C 11 (28.21%) 28 (71.79%)
CD4 (cells/mm3) 471 2 292a 464 2 244a NS
AST (IU/L) 55 2 52.8a 49 2 45.7a NS
ALT (IU/L) 89.6 2 79.1a 77.6 2 57.4a NS
HIV viremia (log 10) 2.4 2 1.0a 2.1 2 0.8a NS
HCV-RNAb 88 (85.48%) 107 (79.78%) NS
Gender
female 19 (18.45) 51 (37.78%)
male 84 (81.55) 84 (62.78%) P = 0.0018d
Time since seroconversion (years) 1990 2 4a 1990 2 3a NS
Total bilirubin (mg/dL) 1.1 2 0.8a 1.2 2 0.9a NS
g-GTP (IU/L) 112.48 2 118.83a 94.44 2 127.06a NS
IVDU 68 (66.02%) 72 (54.14%) NS
a Mean 2 SD
bpositive by Polymerase Chain Reaction with N22 primers.
cNS, not significant.
dChi-square test.
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RESULTS
Using the primers deduced from UTR, which is positioned 3?
to a GC-rich region, TTV DNA was detected in 229 of 238
(96.2%) and in 185 of 226 (81.8%) HIV-1 seropositive patients
and blood donors, respectively. In contrast, using primers
deduced from N22 region, the corresponding figures were 103
of 238 (43.3%; CI 95% = (36.9–49.8)) and 22 of 226 (9.7%; CI
95% = (6.2–14.4]). The detection rate of TTV viremia in HIV-
1-infected subjects was significantly higher than in blood donors
(P  0.005). All sera which tested negative by PCR with UTR
primers were negative also by PCR with N22 primers. Demo-
graphic, virologic and clinical features, were compared between
HIV-1 seropositive patients who were positive for TTV DNA
by PCR with N22 primers and those who were not. These
included: gender, stage of disease, CD4 + T-cell count, abnor-
mal ALT, AST, g-GPT and bilirubin levels, HIV-1 viremia,
presence of HCV infection, time since first HIV seroconversion
and intravenous drug use (IVDU) (Table 1). As the range was
very limited (24–40 years), the patients’ age was not taken into
account in this analysis. TTV infection was more frequent in
male than in female subjects: 84 of 103 (81.5%) patients positive
for TTV DNA were male and 19 (18.4%) were female
(P = 0.00118); the corresponding figures among negative pat-
ients were 84 of 135 (62.2%) and 51 of 135 (37.8%). There
were no significant differences in any clinical or virological
parameters between these groups.
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Table 2 Persistence of TTV DNA in HIV-1-seropositive patients
TTV DNA patients
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
March 1997 +  +   + +     + + + 
June 1997 +  + +  + +       + +
September 1997 +  + + + + +  +  +    
November 1997 + + + + + + + + +  +  + + +
May 1998 + + + + + + + + + + + + + + +
September 1998 + + + + + + + + + + + + + + +
+/, presence/absence of TTV DNA detected by polymerase chain reaction with N22 primers.
Logistic regression analysis was used to identify the same
demographic, virologic and clinical variables associated with
the presence of TTV DNA; this multivariate analysis confirms
the association between TTV DNA and gender, the males
being more frequently positive than females (OR 4.8; 95%
CI = (1,6–8,8–13); P = 0.003).
The possibility of prolonged TTV infection was evaluated
in a retrospective analysis of cryopreserved plasma samples,
obtained over a period of 9–20 months from 15 HIV-1-infected
patients positive for TTV DNA detectable by N22 PCR
(Table 2). TTV viremia was consistently detected in 11 patients
over a period of 5–20 months; in the remaining four patients
intermittent viremia was detected.
DNA amplificates obtained by N22 PCR from 27 randomly
chosen TTV DNA-positive subjects (12 blood donors and 15
HIV-1 seropositive patients) were purified and subjected to
direct sequencing. Phylogenetic analysis of the resulting
sequences together with sequences reported in previous papers
were performed, and the consensus phylogenetic tree is
depicted in Figure 1. TTV sequences from this study segregated
three major groups, namely genotype 1 (G1), genotype 2 (G2)
and genotype 3 (G3), as previously reported. Subtypes of geno-
type 1 (1a and 1b) accounted for six HIV-1-seropositive patients
and six blood donors, and subtypes of the genotype 2 for nine
HIV-1-seropositive patients and four blood donors. The two
sequences that segregated as genotype 3 occurred in one HIV-
1-infected patient and in one blood donor.
DISCUSSION
This study shows that TTV DNA, detected by PCR with UTR
primers was present in 185 of 226 (81.8%) healthy individuals
and in 229 of 238 (96.5%) HIV-1-seropositive patients in Italy,
thereby confirming and extending previous studies indicating
a deep and wide penetration of TTV (with various genotypes)
into the community. Furthermore TTV DNA detectable by
PCR with N22 primers was present in HIV-1-seropositive
patients with a similar prevalence as has been reported for
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Figure 1 Phylogenetic analysis of TTV sequences from HIV-1 ser-
opositive subjects and blood donors (*). Sequences of the N22, TA
278, TX 011, TS 003 and NA 004 prototipe isolates of TT V were taken
from Okamoto et al. (1998) [2], and sequences JA 5 and us16 from
GenBank, accession no. AF 123964 and AF123958.
populations at different risks for hepatitis viruses such as hem-
odialysis, chronic hepatitis C, multiple-transfused patients and
bone marrow transplant recipients [2,4,18]. The prevalence of
TTV viremia observed in this study in healthy blood donors
by N22 PCR (9.7%) was significantly lower than in immu-
nocompromised patients (43.3%) and only slightly lower than
that reported in a recent study on healthy donors in Italy (22%)
[19]. Furthermore, this prevalence in blood donors was very
close to those from Japan (12%) and Germany (13.1%) but
higher than was reported in similar cohorts in the UK (1.9%)
and North America (1%) [2,6,7]. Because of the distinct speci-
ficity of the two PCR methods used in this study we focused
our attention on results obtained by PCR with N22 primers
that, as suggested by several authors, can detect TTV genotypes
associated with hepatitis of unknown etiology [2–4,15].
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Bivariate and multivariate analyses were performed to evalu-
ate the relationships between the presence of TTV DNA and
the demographic and clinical features in HIV-1-infected pati-
ents. In both analyses only male gender was significantly associ-
ated with presence of TTV DNA (P = 0.003). It is interesting
that, up to now, a higher prevalence of TTV viremia in male
subjects was observed only in an Italian study in healthy blood
donors [18]. This suggests that further studies on some epi-
demiological features, such as gender, may be helpful to clarify
the routes of infection.
A high, but not significant, percentage of HIV-1-seropositive
patients with TTV infection had a history of IVDU and thus,
as well as the high rate of viremia in healthy blood donors,
confirms the observations of previous studies [20,21] that the
parenteral route is an important but not the only mode of TTV
spread. Furthermore, TTV infection was not associated with
clinical stage, CD4+ T-cell count, HIV-1 viremia or time since
first seroconversion indicating that clinical variables related to
immunosuppression do not influence the frequency of TTV
viremia. Sequence analysis indicated that genotype distribution
was similar to that reported in Europe, mainly consisting of
genotype G1, G2 and a low rate of G3. In our study no
difference in genotype distribution between HIV-1 patients
and healthy blood donors was observed.
Although the aim of this study was not to evaluate any
pathogenetic role for TTV, an interesting result is the per-
sistence of TTV DNA in plasma samples in all the HIV-1-
infected subjects tested (15 of 15). The prolonged persistence
of TTV viremia, also observed in previous studies in immuno-
competent hosts, could be important in evaluating the patho-
genetic role of the virus in these patients [1,7,18,22]. In
immunocompromised hosts, as shown for other opportunistic
pathogenic agents, TTV could lead to more severe disease or
infection developing into disease.
In conclusion, the immunocompromised host (HIV-1-
infected or iatrogenic) could be a population group in which
further clinical investigations into viral persistence will provide
information on a possible pathogenic role of TTV and its short-
as well as long-term consequences.
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